Phaseline

Companies › Full-Life Technologies UK

Full-Life Technologies UK: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[225Ac]Ac-FL-020
anti-c-MET targeted radioligand therapy (alpha-particle emitter conjugate)
METPhase 1Metastatic Castration-resistant Prostate Cancer; Solid TumorSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06492122[225Ac]Ac-FL-020Phase 1Metastatic Castration-resistant Prostate CancerOncologySep 2027
NCT07873450[225Ac]Ac-FL-020Phase 1Solid TumorOncologyJun 2030

Targets

MET (1)

Companies with the same targets

AstraZeneca Johnson & Johnson (Janssen) Exelixis AbbVie Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Beijing Scitech-Mq Pharmaceuticals IDEAYA Biosciences Shanghai Henlius Biotech DeuterOncology

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.